Abstract:by the experimental team have shown that osteoporosis in type 1 diabetic mice is associated with down-regulation of hypoxia-inducible signaling pathways in bone [2].The hypoxia-inducible factor information pathway is a key pathway for conjugated bone formation and angiogenesis.The results of this research team show that activation of hypoxia signaling pathway can promote bone Objective: To observe bone mineral density, bone volume, bone architecture, bone strength and bone metabolism in type I diabetic osteoporosis mice treated by hypoxia mimicking agent-Deferoxamine/DFO.Method: Type I diabetic mice models were established by injections of streptozotocin.The mice were randomly divided into three groups: control group (normal mice), diabete group (diabetic mice+saline), diabete + DFO group (diabetic mice + DFO).Micro-CT was used to analyse the bone mineral density, bone volume, bone architecture and bone strength of the trabecula in the distal part of femurs.Three point bending test was carried out to evaluate the bone strength.Haematoxylin and eosin (HE) staining was performed to view the alteration in the number of osteoblasts.Real-time PCR was used to detect the mRNA alteration of Runx-2, Osteoclacin, TRAP in tibias.Western blot was used to detect the protein expression alteration of in HIF-1α and VEGF in tibias. Conclusion:Bone loss was partly prevented by DFO treatment in type I diabetic osteoporosis mice, which might be ascribed to increased bone formation via stimulative hypoxia inducible factor singnaling pathway.Results: There was a decrease in bone mineral density, bone volume, bone strength as well as deteriorated trabecular microarchitecture in diabetic mice compared to control group, which were partly restored by DFO treatment.Moreover, DFO treatment increased the number of osteoblasts, mRNA expression levels of Runx-2, Osteoclacin, TRAP, and protein expression levels of HIF-1α and VEGF.development and partially prevent osteoporosis in aged mice and ovariectomized mice.To promote osteoporotic bone defect repair and fracture healing [6-8].Hypoxic mimetic compounds are a class of compounds that activate hypoxic signaling pathways under normoxic conditions, including Deferoxamine (DFO), cobalt chloride, dimethylhexanoyl glycine, etc.The most commonly used is DFO.The role of DFO in inducing angiogenesis and accelerating bone remodeling has been confirmed in several experiments [9-12].The experiment attempted to use DFO to intervene in a mouse model of type 1 diabetes to observe the changes of bone mineral density, bone mass and bone metabolism in mice after activation of hypoxia signaling pathway, and to find a new method for prevention and treatment of osteoporosis in type 1 diabetes.

PPARβ/δ Agonist Alleviates Diabetic Osteoporosis Via Regulating M1/M2 Macrophage Polarization.

PPARβ/δ accelerates bone regeneration in diabetic mellitus by enhancing AMPK/mTOR pathway-mediated autophagy

AR/PCC herb pair inhibits osteoblast pyroptosis to alleviate diabetes‐related osteoporosis by activating Nrf2/Keap1 pathway

Hyperglycemia Induces Endoplasmic Reticulum Stress-Dependent CHOP Expression in Osteoblasts

Osteoking prevents bone loss and enhances osteoblastic bone formation by modulating the AGEs/IGF-1/β-catenin/OPG pathway in type 2 diabetic db/db mice

Regulation of selective PPARγ modulators in the differentiation of osteoclasts.

Deficiency of protein phosphatase 5 resists osteoporosis in diabetic mice

PPARδ activation protects endothelial function in diabetic mice

Exendin-4 and eldecalcitol synergistically promote osteogenic differentiation of bone marrow mesenchymal stem cells through M2 macrophages polarization via PI3K/AKT pathway

Pathophysiological Mechanism of Bone Loss in Type 2 Diabetes Involves Inverse Regulation of Osteoblast Function by PGC-1α and Skeletal Muscle Atrogenes: AdipoR1 as a Potential Target for Reversing Diabetes-Induced Osteopenia

Activation of ROS/MAPKs/NF-κB/NLRP3 and inhibition of efferocytosis in osteoclast-mediated diabetic osteoporosis.

miRNA-seq analysis of high glucose induced osteoblasts provides insight into the mechanism underlying diabetic osteoporosis

PPAR-α Agonist Fenofibrate Prevented Diabetic Nephropathy by Inhibiting M1 Macrophages via Improving Endothelial Cell Function in db/db Mice

Prevention of Bone Loss in Type I Diabetic Osteoporosis Mice by Hypoxia Mimicking Agent Deferoxamine

Analysis of bone metabolic alterations linked with osteoporosis progression in type 2 diabetic db/db mice

Ziyin Bushen Fang improves Diabetic Osteoporosis by Inhibiting Autophagy and Oxidative Stress In vitro and In vivo

Adrenomedullin 2 improves bone regeneration in type 1 diabetic rats by restoring imbalanced macrophage polarization and impaired osteogenesis

Polycytosine RNA-binding protein 1 regulates osteoblast function via a ferroptosis pathway in type 2 diabetic osteoporosis

Effects of Low-Intensity Pulsed Electromagnetic Fields on Bone Microarchitecture, Mechanical Strength and Bone Turnover in Type 2 Diabetic Db/db Mice

Overexpression of SENP3 promotes PPAR-γ transcription through the increase of HIF-1α stability via SUMO2/3 and participates in molecular mechanisms of osteoporosis

Restoring bone-fat equilibrium: Baicalin's impact on P38 MAPK pathway for treating diabetic osteoporosis